Bristol-Myers Squibb Company (BMY)

Return on equity (ROE)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Net income (ttm)	US$ in thousands	-8,948,000	-7,258,000	-6,541,000	-6,148,000	8,025,000	8,285,000	7,963,000	7,311,000	6,327,000	6,677,000	6,617,000	6,251,000	6,994,000	-5,405,000	-5,079,000	-6,219,000	-9,015,000	-44,000	-563,000	954,000
Total stockholders’ equity	US$ in thousands	16,335,000	17,142,000	17,015,000	16,490,000	29,430,000	28,998,000	31,973,000	31,824,000	31,061,000	32,671,000	32,600,000	31,580,000	35,946,000	37,213,000	36,808,000	37,605,000	37,822,000	50,158,000	49,094,000	49,911,000
ROE		-54.78%	-42.34%	-38.44%	-37.28%	27.27%	28.57%	24.91%	22.97%	20.37%	20.44%	20.30%	19.79%	19.46%	-14.52%	-13.80%	-16.54%	-23.84%	-0.09%	-1.15%	1.91%

December 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-8,948,000K ÷ $16,335,000K
= -54.78%

Bristol-Myers Squibb Company's return on equity (ROE) has shown significant fluctuations over the past five years. The ROE was consistently negative from June 2020 to March 2022, indicating that the company was not generating satisfactory returns on shareholder equity during this period.

However, starting from December 2022, there was a notable improvement in the ROE, with positive figures observed for each subsequent quarter until March 2024. The ROE peaked at 28.57% in September 2023, indicating a strong performance and efficient utilization of the company's equity.

Subsequently, there was a sharp decline in the ROE, dropping to negative figures from March 2024 to December 2024. The negative ROE values during this period suggest that the company's earnings were not sufficient to cover its equity investments, potentially raising concerns about its financial health and operational efficiency.

Overall, Bristol-Myers Squibb Company's ROE has displayed volatility and inconsistency, with periods of strong performance interspersed with periods of underperformance. Investors and stakeholders may want to closely monitor the company's financial strategies and operational performance to assess its ability to generate sustainable returns on shareholder equity in the future.